BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. DESIGN AND METHODS: We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. RESULTS: Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). CONCLUSIONS: In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. DESIGN AND METHODS: We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. RESULTS: Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). CONCLUSIONS: In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
Authors: A M Carella; M Cavaliere; E Lerma; R Ferrara; L Tedeschi; A Romanelli; M Vinci; G Pinotti; P Lambelet; C Loni; S Verdiani; F De Stefano; M Valbonesi; M T Corsetti Journal: J Clin Oncol Date: 2000-12-01 Impact factor: 44.544
Authors: Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres Journal: N Engl J Med Date: 2010-11-04 Impact factor: 91.245
Authors: Jacob P Smeltzer; Amanda F Cashen; Qin Zhang; Andrew Homb; Farrokh Dehdashti; Camille N Abboud; John F Dipersio; Keith E Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; Nancy L Bartlett; Todd A Fehniger Journal: Biol Blood Marrow Transplant Date: 2011-05-03 Impact factor: 5.742
Authors: P Brice; M Divine; D Simon; B Coiffier; V Leblond; M Simon; L Voilat; A Devidas; F Morschhauser; P Rohrlich; M André; E Lepage; C Ferme Journal: Ann Oncol Date: 1999-12 Impact factor: 32.976
Authors: Alison J Moskowitz; Joachim Yahalom; Tarun Kewalramani; Jocelyn C Maragulia; Jill M Vanak; Andrew D Zelenetz; Craig H Moskowitz Journal: Blood Date: 2010-08-23 Impact factor: 22.113
Authors: Heidi Mocikova; Robert Pytlik; Jana Markova; Katerina Steinerova; Zdenek Kral; David Belada; Marie Trnkova; Marek Trneny; Vladimir Koza; Jiri Mayer; Pavel Zak; Tomas Kozak Journal: Leuk Lymphoma Date: 2011-06-23
Authors: M Damlaj; S Ghazi; G Syed; T Pasha; G Gmati; H Salama; O Ali; K A Abuelgasim; M Al-Zahrani; A Hejazi; A Al Askar Journal: Bone Marrow Transplant Date: 2017-07-10 Impact factor: 5.483
Authors: Anton Hagenbeek; Hans Mooij; Josée Zijlstra; Pieternella Lugtenburg; Gustaaf van Imhoff; Marcel Nijland; Sanne Tonino; Martin Hutchings; Marjolein Spiering; Roberto Liu; Harm van Tinteren; Marie José Kersten Journal: Haematologica Date: 2018-10-31 Impact factor: 9.941
Authors: Gary A Ulaner; Debra A Goldman; Craig S Sauter; Jocelyn Migliacci; Joshua Lilienstein; Mithat Gönen; Heiko Schöder; Craig H Moskowitz; Andrew D Zelenetz Journal: Radiology Date: 2015-06-02 Impact factor: 11.105
Authors: A Stamatoullas; P Brice; M S Gueye; S Mareschal; P Chevallier; R Bouabdallah; S Nguyenquoc; S Francois; P Turlure; P Ceballos; H Monjanel; J-H Bourhis; G Guillerm; M Mohty; P Biron; J Cornillon; K Belhadj; C Bonmati; M-S Dilhuydy; A Huynh; M Bernard; M-L Chrétien; R Peffault de Latour; H Tilly Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: L Castagna; R Crocchiolo; L Giordano; S Bramanti; C Carlo-Stella; B Sarina; A Chiti; E Mauro; S Gandolfi; E Todisco; M Balzarotti; A Anastasia; M Magagnoli; E Brusamolino; A Santoro Journal: Bone Marrow Transplant Date: 2015-01-26 Impact factor: 5.483